List view / Grid view
In this issue are articles on the development of mRNA vaccines against latent viruses, how memory B cell antibody-based treatments can help to fight cancer and the potential of AI in drug discovery. Also included are pieces on biotherapeutics, immuno-oncology and assays.
Michael Sassano and Anthony DeMeo from Somai Pharmaceuticals discuss using ethosomes as an improved method to deliver cannabinoids to the human body.
In this exclusive piece, Adrien Châtillon, Co-Founder and CEO of Actipulse Neuroscience, explores the future of treatment for diseases that impact mental health.
In this exclusive Q&A, Dr Paulina Nunez-Badinez, Scientific Researcher at Bayer AG, discusses pre-clinical research of pain related to endometriosis and why there is a lack of research around this area.
Dr Greg Neely, University of Sydney, explains how he and his team used pooled whole genome CRISPR activation screening to identify LRRC15 as a SARS-CoV-2 spike-interacting protein.
In this Q&A, Professor Ross King from the University of Cambridge, UK, discusses how a new machine learning approach could aid drug discovery and development. The method learns from multiple problems and improves performance while it learns.
According to a new study, a metabolic enzyme studied in cancer biology is key for T-cell function, offering a novel target for anti-inflammatory therapeutics. Dr Jeffrey Rathmell and Ayaka Sugiura from Vanderbilt University in the US discuss their study with Drug Target Review and why inhibiting or genetically deleting the…
In this article, Patrick Kendall, Scientific Advisor for Artelo Biosciences, outlines why future treatment of cancer anorexia-cachexia syndrome may lie with drugs in development offering a mechanistic approach.
With operations in over 100 countries worldwide, GenScript Biotech, an industry leader in biotechnology reagent services, has established a new UK office in the Oxford area to better connect with the UK biosciences sector.
Dr Alasdair Gunn and Natalie Bath from Adaptimmune explain how flow cytometry provides a useful tool for the development of immuno-oncology therapies. They also explore how they use this method for translational research of the company’s SPEAR T-cell products.
With a range of tools available to scientists in the field of therapeutic discovery and development, flow cytometry presents an advantageous method to sort cells based on subtle differences. To find out more, Drug Target Review’s Victoria Rees spoke with Dr Peter O’Toole, Head of Imaging and Cytometry and Dr…
In this article, Dr Shishir Chundawat and Aron Gyorgypal from Rutgers University, US, explain how they developed a new process analytical technology (PAT) system for the automated monitoring of antibody N-glycosylation.
Three-dimensional (3D) biopsy culture models could save the drug discovery industry time and money. In this article, Johanna Niklander, University of Helsinki and Medical University of Graz, and Dr Beate Rinner, Medical University of Graz, outline a recent study they took part in, investigating long-term 3D tissue cultures from human…
In this article, Dmytro Spilka explores three promising biotechs that have seen growth in the last year and why they may continue to garner interest.
Professors Piergiorgio Percipalle and Gennaro Esposito summarise their study which revealed two nanobodies that could inhibit a non-structural protein of SARS-CoV-2.
